看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
( e; _& H8 N: q4 I: i% k5 p3 X8 H: r
( L" k- Q0 T( o H: ]0 O. i" S4 p9 p5 A9 m- Y
Currently available feasibility data for possible combination strategies.
* `: Y0 [- n% L* l8 {————————————————————————————————
/ n, n* u% I0 P% n% O) j, a* \Combination Feasibility according to preliminary data
" i4 K, B" i) z- Z——————————————————————————————————
" s7 V( A' D4 x2 K; M) DBevacizumab + sorafenib Yes, reduced dose
5 f$ [5 C) `, A" RBevacizumab + sunitinib† No ' ?! x! i1 q7 U
Bevacizumab + temsirolimus Yes
- N9 z D7 `# nBevacizumab + everolimus Yes
: b/ K! U8 ~) N CSorafenib + sunitinib ? . D0 j" x; _4 A8 e$ n: p
Sorafenib + temsirolimus Yes, reduced dose
z$ E6 h, n5 K- r, T$ g4 {4 [( e$ uSorafenib + everolimus Yes, reduced dose
9 g' o& ]9 i' q ySunitinib + temsirolimus† No ' r z/ v3 }& O, V
Sunitinib + everolimus ?
- g6 L9 ^* b( e( q0 MTemsirolimus + everolimus ? + A& ~+ E1 w1 X$ x( R: {
————————————————————
7 F) F( @; d0 D* E- M†Led to US FDA warning.4 G$ [9 U$ D6 T3 m
?: As yet unattempted combination.1 `6 N5 T6 s1 f2 T% _2 e2 ~% D" o; v
|